Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to try to develop new blood tests that may help doctors identify if a drug is hurting a person's liver.


Clinical Trial Description

Our hypothesis is that there are liver-specific particles, called mRNA, that are identifiable in a person's blood sample during liver injury caused by some drugs. The purpose of this study is to try to develop new blood tests that may help doctors identify if a drug is hurting a person's liver, perhaps early in the process before significant injury or illness have occurred. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01000766
Study type Observational
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase N/A
Start date September 2009
Completion date December 2013

See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT00360646 - Drug-Induced Liver Injury (DILI) Network Retrospective
Recruiting NCT05789797 - Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
Terminated NCT02686385 - Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury N/A
Active, not recruiting NCT04269486 - A Multicenter Observational Study on Safety of the Herbal Medicines at Inpatient Setting
Recruiting NCT06192589 - Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions Phase 1
Completed NCT00616018 - Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days Phase 4
Withdrawn NCT01137591 - Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever N/A